⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 13, 2024VaccinesOpen Access

Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study

Agnieszka Bogacz-Piaseczyńska Andrzej Bożek Magdalena Krupka-Olek Aleksandra Kawczyk‐Krupka Jolanta Zalejska–Fiolka Giorgio Walter Canonica

View Full Paper

Ask AI

Bookmark

Share

Abstract

Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bogacz-Piaseczyńska et al. (2024) studied this question.

synapsesocial.com/papers/68e58936b6db64358752591e https://doi.org/10.3390/vaccines12091046

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta‐AnalysisRCT · 2026
2Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisRCT · 2014 · 1,421 citations
3Dupilumab in the treatment of severe adopic dermatitis and respiratory allergy: a case report2024
4Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life2024 · 5 citations
5Dupilumab as Therapeutic Option in Polysensitized Atopic Dermatitis Patients Suffering from Food Allergy2024 · 3 citations